Ilyang Pharmaceutical Co.,Ltd

007570.KS · Korea Exchange · KRW

6.850,00KRW

+80,00 (+1,18 %)Stand 10. Nov., 6:30

Vortag 6.770,00

Kennzahlen

Eröffnung
6.900,00
Vortag
6.770,00
Tagesspanne
6.750,00 – 6.970,00
52 Wochen
6.500,00 – 16.240,00
Volumen
13.218
Ø Volumen
25.116
Börsenwert
122,79 Mrd. KRW
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
0,4
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gerade nicht verfügbar.

Dividenden und Splits

Gerade nicht verfügbar.

Aktiensplits

Gerade nicht verfügbar.

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

Gerade nicht verfügbar.

Vergleichbare Unternehmen

Gerade nicht verfügbar.

Über das Unternehmen

Headquartered in Yongin, South Korea, Ilyang Pharmaceutical Co.,Ltd is a prominent pharmaceutical enterprise that has been operating since its establishment in 1946. The company, which was formerly known as Il-Yang Pharm. Ind. Co. until its renaming in May 1991, primarily conducts its business in South Korea. It develops and provides a comprehensive portfolio of medicines addressing various therapeutic areas, such as oncology, cardiovascular health, endocrine and metabolic conditions, women's health (including female hormone treatments and cheonjiyang), urology, ophthalmology, liver diseases, pain and inflammation, digestive system issues, dermatological complaints, and respiratory illnesses. Their pharmaceutical offerings also extend to nutrient infusions, neurological medications, antibiotics, antifungals, insecticides, and vaccines. In addition to medicinal products, Ilyang manufactures a range of consumer health items, including health drinks, dietary supplements, health foods, cosmetics, and other beverages. The company is also a producer of numerous pharmaceutical raw materials, specifically various aluminum and magnesium compounds. Ilyang Pharmaceutical has an international footprint, exporting its diverse product range to roughly 14 countries worldwide.

CEO
Dong-Yeon Kim
Mitarbeitende
665
Hauptsitz
Yongin, GY, KR
Sektor
Healthcare
Branche
Drug Manufacturers - Specialty & Generic
Börsengang
4. Jan. 2000

Nachrichten

Gerade nicht verfügbar.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.